HUP0301093A2 - Kemokinreceptorhoz kötżdż heterociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk - Google Patents

Kemokinreceptorhoz kötżdż heterociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Info

Publication number
HUP0301093A2
HUP0301093A2 HU0301093A HUP0301093A HUP0301093A2 HU P0301093 A2 HUP0301093 A2 HU P0301093A2 HU 0301093 A HU0301093 A HU 0301093A HU P0301093 A HUP0301093 A HU P0301093A HU P0301093 A2 HUP0301093 A2 HU P0301093A2
Authority
HU
Hungary
Prior art keywords
general formula
group
oxygen
nitrogen
meanings
Prior art date
Application number
HU0301093A
Other languages
English (en)
Inventor
Bem Atsma
David Bogucki
Gary Bridger
Jason Crawford
Rosaria Maria Di Fluri
Curtis Harwig
Al Kaller
Ernest J. Mceachern
Siqiao Nan
Dominique Schols
Renato Skerlj
Christopher Dennis Smith
Trevor R. Wilson
Yuanxi Zhou
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc. filed Critical Anormed Inc.
Publication of HUP0301093A2 publication Critical patent/HUP0301093A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

A találmány tárgyát kemokinreceptorokra ható, (I)-(IV) általánosképletű összetett tercier aminok képezik. (I) általános képletben az Agyűrű adott esetben heteroatomot tartalmaz, ami lehet nitrogén-,oxigén- vagy kénatom, a szaggatott vonal adott esetben meglévőtelítetlenségre utal; R1, R2 és R3 jelentése neminterferálószubsztituens; k jelentése 0-4; m jelentése 0-2; L1 jelentése 1,5-10 Améretű kötőcsoport; X jelentése helyettesítetlen vagy helyettesítettszén- vagy nitrogénatom vagy oxigén- vagy kénatom; Ar jelentése aromáscsoport; n jelentése egymástól függetlenül 0-2; R jelentése egymástólfüggetlenül hidrogénatom vagy 1-6 szénatomos alkilcsoport; Y jelentésearomás, heteroaromás vagy más heterociklusos csoport. A (II) általánosképletben R, m, n, Ar és Y jelentése azonos az (1) általános képletnéltett meghatározásokkal; Z jelentése egymástól függetlenül CR2, NRáltalános képletű csoport, oxigén- vagy kénatom, azzal a feltétellel,hogy csak két Z jelentése lehet más, mint CR2 képletű csoport; L2jelentése 1.5-8 A méretű kapcsolócsoport. A (III) általános képletbenW1 jelentése 5-6 tagú egygyűrűs vagy 8-12 tagú kondenzált kétgyűrűs,helyettesítetlen vagy helyettesített, legalább egy heteroatomot - amilehet nitrogén-, oxigén- vagy kénatom - tartalmazó gyűrűs rendszer; W2jelentése hidrogénatom, adott esetben helyettesített, 1-6 szénatomosalkil-, adott esetben helyettesített aromás vagy heterociklusoscsoporttal helyettesített, 0-6 szénatomos alkil-, adott esetbenhelyettesített, 0-6 szénatomos alkil-amino- vagy 3-7 szénatomoscikloalkil-amino-, adott esetben helyettesített karbonil- vagyszulfonilcsoport; Ar, R és n jelentése azonos az (I) általános képletleírásánál tett meghatározásokkal; és a B gyűrűt telített vagytelítetlen, 1-2 heteroatomot - ami lehet nitrogén-, oxigén vagykénatom - tartalmazó öttagú gyűrű. A (IV) általános képletben W1 és W2jelentése a 13. igénypontban meghatározott; Ar, R és n jelentése az 1.igényontban meghatározott; CD-gyűrűrendszer egy 10 tagú, adott esetbenegy vagy két heteroatomot - ami lehet nitrogén-, oxigén- vagy kénatom- tartalmazó kondenzált gyűrűs rendszer. Ó
HU0301093A 2000-09-15 2001-09-17 Kemokinreceptorhoz kötżdż heterociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk HUP0301093A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23289100P 2000-09-15 2000-09-15
US23451000P 2000-09-22 2000-09-22
PCT/CA2001/001326 WO2002022600A2 (en) 2000-09-15 2001-09-17 Chemokine receptor binding heterocyclic compounds

Publications (1)

Publication Number Publication Date
HUP0301093A2 true HUP0301093A2 (hu) 2003-09-29

Family

ID=26926422

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301093A HUP0301093A2 (hu) 2000-09-15 2001-09-17 Kemokinreceptorhoz kötżdż heterociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk

Country Status (22)

Country Link
US (3) US6864265B2 (hu)
EP (1) EP1317445B1 (hu)
JP (1) JP2004508422A (hu)
KR (1) KR20030029998A (hu)
CN (1) CN1457339A (hu)
AT (1) ATE425157T1 (hu)
AU (2) AU9156901A (hu)
BR (1) BR0113930A (hu)
CA (1) CA2419224A1 (hu)
DE (1) DE60137944D1 (hu)
ES (1) ES2325909T3 (hu)
HK (1) HK1052011A1 (hu)
HU (1) HUP0301093A2 (hu)
IL (1) IL154227A0 (hu)
MX (1) MXPA03002326A (hu)
NO (1) NO20031179L (hu)
NZ (1) NZ524420A (hu)
PL (1) PL360932A1 (hu)
RU (1) RU2289581C2 (hu)
SG (1) SG126007A1 (hu)
TR (1) TR200300322T2 (hu)
WO (1) WO2002022600A2 (hu)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9156901A (en) * 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
US6734191B2 (en) 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2002022599A2 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
MXPA04000982A (es) 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
MXPA04006136A (es) * 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
US7176227B2 (en) 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
US7399776B2 (en) 2003-04-02 2008-07-15 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
WO2004091518A2 (en) 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
US7498323B2 (en) * 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
US7550484B2 (en) 2003-04-22 2009-06-23 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
CN1829709A (zh) * 2003-08-01 2006-09-06 健亚生物科技公司 对抗黄病毒的双环咪唑衍生物
EP1708703A4 (en) 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
CN1950343B (zh) * 2004-03-10 2013-06-19 株式会社吴羽 胺系碱性化合物及其用途
CA2558389C (en) * 2004-03-15 2013-10-08 Anormed, Inc. Process for the synthesis of a cxcr4 antagonist
EP1732905A1 (en) * 2004-03-31 2006-12-20 Lexicon Genetics Incorporated 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
CA2577100A1 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
BRPI0514487A (pt) * 2004-08-19 2008-06-17 Colgate Palmolive Co método de preparar uma composição, e, composição
US7951816B2 (en) * 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
EP1793825A4 (en) * 2004-09-24 2009-12-09 Smithkline Beecham Corp CHEMICAL COMPOUNDS
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2006076529A1 (en) * 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
EP1942890A4 (en) 2005-06-15 2009-08-26 Genzyme Corp CHEMOKINE RECEPTOR BINDING COMPOUNDS
JP2009500451A (ja) * 2005-07-11 2009-01-08 スミスクライン ビーチャム コーポレーション ピラノピリジン化合物
BRPI0615180A2 (pt) 2005-08-19 2011-05-03 Genzyme Corp método para intensificar a quimioterapia
ES2407115T3 (es) * 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
US7671069B2 (en) 2006-03-30 2010-03-02 Chemocentryx, Inc. Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
CN101495115A (zh) * 2006-08-02 2009-07-29 健赞股份有限公司 组合治疗
JP2010507567A (ja) * 2006-08-07 2010-03-11 ジェンザイム・コーポレーション 併用療法
WO2009036341A2 (en) * 2007-09-14 2009-03-19 The Regents Of The University Of Michigan Compositions and methods relating to hiv protease inhibition
PE20110164A1 (es) * 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
JP2012502048A (ja) * 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
EP2646430B1 (en) 2010-12-03 2016-09-21 Emory University Chemokine cxcr4 receptor modulators and uses related thereto
CN102603683B (zh) * 2012-02-10 2014-04-09 山东大学 一种呋喃类化合物及其制备方法与应用
CN104478795A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种2-氯烟醛的制备方法
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
CN104945313A (zh) * 2015-06-19 2015-09-30 洪帅金 一种2-甲基-3-溴吡啶的制备方法
BR112018007021B1 (pt) * 2015-10-06 2024-01-09 Proteostasis Therapeutics, Inc Composto, composição compreendendo os ditos compostos e uso dos mesmos para tratar fibrose cística
CN105198802A (zh) * 2015-11-03 2015-12-30 江苏梦得电镀化学品有限公司 一种2-甲基-3-溴吡啶的制备方法
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
CN112110853A (zh) * 2020-09-23 2020-12-22 海南梵圣生物科技有限公司 一种合成3-羟基-2-吡啶甲酸及其衍生物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
BR9810600A (pt) 1997-07-16 2000-07-11 Ciba Sc Holding Ag Compostos espiro-poliglicidila e seu uso em resinas epóxi
JP2002501898A (ja) * 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性の環状アミン調節剤
JPH11269146A (ja) * 1998-03-24 1999-10-05 Mitsui Chem Inc 分化誘導剤
JP2002535256A (ja) * 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US6362201B1 (en) * 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
EP1163238B1 (en) * 1999-03-24 2006-05-31 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2002022599A2 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU9156901A (en) * 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds

Also Published As

Publication number Publication date
CA2419224A1 (en) 2002-03-21
NO20031179D0 (no) 2003-03-14
IL154227A0 (en) 2003-07-31
EP1317445B1 (en) 2009-03-11
BR0113930A (pt) 2003-06-24
PL360932A1 (en) 2004-09-20
WO2002022600A3 (en) 2002-05-10
KR20030029998A (ko) 2003-04-16
TR200300322T2 (tr) 2003-09-22
US20030018046A1 (en) 2003-01-23
MXPA03002326A (es) 2003-06-06
NZ524420A (en) 2005-04-29
EP1317445A2 (en) 2003-06-11
CN1457339A (zh) 2003-11-19
US7396840B2 (en) 2008-07-08
WO2002022600A2 (en) 2002-03-21
NO20031179L (no) 2003-03-14
ATE425157T1 (de) 2009-03-15
HK1052011A1 (zh) 2003-08-29
ES2325909T3 (es) 2009-09-24
RU2289581C2 (ru) 2006-12-20
US7084155B2 (en) 2006-08-01
AU2001291569B2 (en) 2007-07-26
SG126007A1 (en) 2006-10-30
JP2004508422A (ja) 2004-03-18
US20040220207A1 (en) 2004-11-04
US6864265B2 (en) 2005-03-08
US20060128750A1 (en) 2006-06-15
AU9156901A (en) 2002-03-26
DE60137944D1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
HUP0301093A2 (hu) Kemokinreceptorhoz kötżdż heterociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0302960A2 (hu) Kemokinreceptorhoz kötődő heterociklusos vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0301094A2 (hu) Kemonikinreceptorhoz kötżdż heterociklusos vegyületek, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP9702034A2 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek valamint e vegyületeket tartalmazó gyógyászati készítmények
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
TW200612920A (en) Novel imidazolidine derivatives
HUP9702036A1 (hu) Leukocitaadhéziót gátló és VLA-4-antagonista vegyületek valamint e vegyületeket tartalmazó gyógyászati készítmények
DK1427720T3 (da) 3-substitueret-4-pyrimidonderivater
DK1773757T3 (da) TRPV1 agonister, formuleringer indeholdende dem og anvendelser deraf
HUP0302422A2 (hu) Hashajtó hatású kompozíció és alkalmazása gyógyszer előállítására
MY154772A (en) Harmful arthropod control composition, and fused heterocyclic compound
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
HUP0300782A2 (hu) Nitrogéntartalmú heterociklusos kaszpáz inhibitorok, eljárás az elżállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200971063A1 (ru) Ариламидпиримидоновые соединения
JO2616B1 (ar) مركبات ثلاثية الحلقات جديدة، طريقة من أجل تحضيرها ومركباتها الصيدلانية
JO2808B1 (en) Compounds and their preparation and pharmaceutical compounds
NO20061334L (no) Indanyl-piperanzinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
IL159554A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
MX2021011376A (es) Derivados de rapamicina que contienen isotiazolidina 1,1 - dioxido y 1,4 - butan sultona y sus usos.
ATE519818T1 (de) Reversibel thermochrome zusammensetzung
MX2022003656A (es) Compuestos farmaceuticos.
HUP0300758A2 (hu) Kalcilitikus vegyületek és alkalmazásuk kalciumreceptor antagonistákként
HUP0303127A2 (hu) Új heterociklusos-vagy benzol-liponsav-származékok, ezek előállítása és gyógyszerként való alkalmazásuk
ATE283042T1 (de) Parenterale lösungen enthaltend propofol (2,6- diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6- dianhydro-d-glucitol als lösungsmittel
HUP0102350A2 (hu) Propenil-cefalosporin-származékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees